← Back to Search

Cannabinoid

CBD for Social Anxiety Disorder

Phase < 1
Waitlist Available
Led By David Tolin, Ph.D.
Research Sponsored by Hartford Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary diagnosis of SAD according to the DIAMOND
At least moderate severity of SAD as evidenced by a DIAMOND severity rating of 4 (moderate) or higher
Timeline
Screening 3 weeks
Treatment Varies
Follow Up single session (2.5 hours)

Summary

This trial will look at how CBD affects fear levels in people with social anxiety disorder.

Who is the study for?
This trial is for adults over 18 with social anxiety disorder (SAD) of at least moderate severity. Participants must be able to understand English as the study materials are only in English. They should not be on medications that interact with cannabidiol (CBD).
What is being tested?
The study tests if oral CBD can help reduce fear more effectively than a placebo during a process called fear extinction, which is part of therapy for SAD.
What are the potential side effects?
Potential side effects from CBD may include tiredness, diarrhea, changes in appetite or weight, but specific side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Social Anxiety Disorder.
Select...
My social anxiety is rated moderate or worse.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~single session (2.5 hours)
This trial's timeline: 3 weeks for screening, Varies for treatment, and single session (2.5 hours) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Distress ratings
Skin conductance

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CannabidiolExperimental Treatment2 Interventions
600 mg oral cannabidiol
Group II: PlaceboPlacebo Group2 Interventions
Placebo capsules

Find a Location

Who is running the clinical trial?

Hartford HospitalLead Sponsor
138 Previous Clinical Trials
19,377 Total Patients Enrolled
David Tolin, Ph.D.Principal InvestigatorHartford Hospital
1 Previous Clinical Trials
22 Total Patients Enrolled
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top